Biggest News Aggregation in the World
📰 Invo Bioscience News

Page 4 - Invo Bioscience News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Invo Bioscience. Real-time updates on events, politics, business and more.

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Reviewing InVivo Therapeutics (NASDAQ:NVIV) and Invo Bioscience (OTCMKTS:IVOB)

Invo Bioscience (OTCMKTS:IVOB – Get Rating) and InVivo Therapeutics (NASDAQ:NVIV – Get Rating) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, analyst recommendations, valuation and risk. Insider and Institutional Ownership 18.6% of InVivo Therapeutics shares […]
United Kingdom United States Invo Bioscience Company Profile Get Rating Bioscience Inc Invivo Therapeutics Holdings Corp Holding Warming

INVO Bioscience, Inc. (NASDAQ:INVO) Short Interest Up 22.5% in May

INVO Bioscience, Inc. (NASDAQ:INVO – Get Rating) was the recipient of a large increase in short interest during the month of May. As of May 15th, there was short interest totalling 71,800 shares, an increase of 22.5% from the April 30th total of 58,600 shares. Based on an average trading volume of 38,800 shares, the […]
United States Bioscience Inc Virtu Financial Zacks Investment Research Susquehanna International Group Connors Investor Services Inc

INVO Bioscience (NASDAQ:INVO) Lifted to Buy at Zacks Investment Research

INVO Bioscience (NASDAQ:INVO – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Friday, Zacks.com reports. The firm currently has a $1.25 target price on the stock. Zacks Investment Research‘s target price would indicate a potential upside of 16.28% from the stock’s current […]
United States Claude Ranoux Maxim Group Bioscience Inc Virtu Financial Zacks Investment Research

INVO Bioscience (NASDAQ:INVO) Lowered to "Hold" at Zacks Investment Research

INVO Bioscience (NASDAQ:INVO – Get Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Thursday, Zacks.com reports. According to Zacks, “INVO Bioscience is a medical device company, headquartered in Beverly, Massachusetts, focused on creating simplified, lower cost treatment options for patients diagnosed with infertility. […]
United States Claude Ranoux Maxim Group Bioscience Inc Virtu Financial Zacks Investment Research

Maxim Group Lowers INVO Bioscience (NASDAQ:INVO) Price Target to $3.00

INVO Bioscience (NASDAQ:INVO – Get Rating) had its price target lowered by stock analysts at Maxim Group to $3.00 in a report issued on Thursday, Stock Target Advisor reports. Maxim Group’s price objective points to a potential upside of 200.00% from the company’s current price. INVO has been the subject of a number of other […]
United States Bioscience Inc Virtu Financial Zacks Investment Research Susquehanna International Group Connors Investor Services Inc

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science